Both flumatinib and radotinib belong to second‐generation ABL1 kinase inhibitors and have been approved for Ph‐positive CML‐CP in China and Korea, respectively. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.